Abstract
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion (MAST3, p = 6.9×10-7 and GAB2, p = 2.0×10-6). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS—versus treatment for the initial management of patients with low-risk PC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
P50CA180995 (William J. Catalona) 08/01/15 - 07/31/20 NIH/NCI SPORE in Prostate Cancer PI on the SPORE grant, Center for Inherited Disease Research (CIDR) award from the NCI for patient sample genotyping (X01HG009642), Urological Research Foundation (William J. Catalona), NorthShore University Health System, Evanston, IL, USA (Brian T. Helfand). Additional support was provided by award numbers R01CA158627 and R01CA195505 (Leonard S. Marks), P50 CA186786 (Todd M. Morgan), UL1 TR000445 from NCATS/NIH for Vanderbilt REDCap (Daniel A. Barocas), P50 CA097186 and K05 CA175147 (Janet L. Stanford), and U01 CA113913 (Martin G. Sanda) from the National Institute of Health, and W81XWH-13-2-0074 (Peter R. Carroll) from the Department of Defense.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Scientific Review (IRB) Committee. The approval number is STU00077147, which was most recently given annual approval on 7/8/2021.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Support: NIH grant P50CA180995; CIDR Contract # HHSN268201700006I
Data Availability
The MEGA data analyzed in this publication have been deposited in dbGap and are accessible through dbGap Study Accession number phs002056.v1.p1.
